Dengue Vaccine Effectiveness: Results from a Six-Year Population-Based Cohort Study in Southern Brazil
CARVALHO, D. S.; Luhm, K. R.; Shimakura, S. E.; Raboni, S. M.; Vieira da Costa-Ribeiro, M. C.; Diaz-Quijano, F. A.; de Mello, A. M.; Roberto da Silva, L.; Buffon, M. d. C. M.; Maluf, E. M. C. P.; Graeff, G.; Preto, C.; de Almeida, G. A.; de Sousa, G. A.; Krainski, E. T.; Evans, A. A.; de Carvalho, D. S.
Show abstract
The alarming growth of dengue worldwide and its social and economic impact have demanded more effective responses for its prevention and control. Currently, the first vaccine approved in Brazil for its prevention, Dengvaxia(R), was administered to a target population of around 500,000 residents in southern Brazil. This study reports its effectiveness after a six-year follow-up period from August 2016 to July 2022. Dengue vaccination campaign was carried out in a target population of individuals aged 15-27 in 28 municipalities and 9-44 years in the other two. In this population-based cohort study, exposure to the vaccine included groups with different numbers of doses and adherence to the complete schedule. The primary outcome was probable dengue case. Other endpoints included laboratory- confirmed dengue, serotype, dengue with warning signs or severe illness, and hospitalization. Approximately 60.4% of the participants received at least one vaccine dose. A total of 50,658 probable dengue cases (PDC) were notified of which 15,131 were laboratory-confirmed dengue cases. Overall effectiveness for at least one dose was 33.7% (95% CI: 32.5-34.9) for PDC and 20.1% (95% confidence interval [CI]: 17.1-22.9) for laboratory-confirmed cases. Greater vaccine effectiveness was observed in older individuals and for the DENV-4 and DENV-1 serotypes. The vaccine showed no effectiveness against DENV-2; no DENV-3 cases occurred. A lower hospitalization rate was observed among the vaccinated group. Differences in the incidence of severe dengue cases and warning signs could not draw a definite conclusion. Vaccination was associated with a one-third reduction in the incidence of probable dengue cases. By serotypes, the reduction was significant only for DENV-1 and DENV-4. Author SummariesOutcomes resulting from dengue mass vaccination remains limited. Study on Dengvaxia(R)s effectiveness in a target population of 501,000 with unknown serostatus. Dengue risk reduction was significant for DENV-1 and DENV-4.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua 96%
- Distinguishing non severe cases of dengue from COVID-19 in the context of co-epidemics: a cohort study in a SARS-CoV-2 testing center on Reunion island 95%
- Assessment of the new World Health Organization’s dengue classification for predicting severity of illness and level of healthcare required 95%
Similar papers in this journal
Similar papers in this journal
- Genomic Characterization of Dengue Virus Outbreak in 2022 from Pakistan 95%
- Development of the Sm14/GLA-SE - schistosomiasis vaccine candidate: An open, not placebo-controlled, standardized dose immunization phase Ib clinical trial targeting healthy young women 93%
- Systematic review and meta-analysis of yellow fever vaccine in elderly population 92%
Similar papers in this journal
- Epidemiological and virological factors determining dengue transmission in Sri Lanka during the COVID-19 pandemic 96%
- U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022 93%
- Genomic sequencing and neutralizing serological profiles during acute dengue infection: A 2017 cohort study in Nepal 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.